Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phosphorylated cyclocarya paliurus polysaccharide (low ds) is a structurally modified natural polysaccharide derived from the leaves of *Cyclocarya paliurus*, a plant commonly known as the sweet tea tree. This specific variant is characterized by a low degree of substitution (ds) of phosphate groups. In preclinical research, particularly in murine models of dextran sulfate sodium (DSS)-induced ulcerative colitis, it has demonstrated significant anti-inflammatory and gut-regulatory activities. Its mechanism of action involves the preservation of the intestinal barrier by upregulating the expression of mucus barrier proteins such as MUC-2 and tight junction proteins like occludin and claudin-1. Furthermore, it suppresses pro-inflammatory signaling through the inhibition of the NF-κB pathway and the NLRP3 inflammasome, leading to reduced production of cytokines like TNF-α and IL-6. It also positively modulates the gut microbiota composition, increasing microbial diversity and the production of short-chain fatty acids (SCFAs).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phosphorylated cyclocarya paliurus polysaccharide (low ds).